Development and Validation of a Model to Predict Recurrence in Patients With Stage IIIA Melanoma.
BACKGROUND Patients with stage IIIA cutaneous melanoma have relatively favorable prognoses (5-and 10-year overall survival probabilities of 93% and 88%, respectively), yet they are considered for systemic adjuvant therapy. Identifying the subset of patients at highest risk of recurrence could limit adjuvant treatment-r...